June 12, 2020EP Europace
Predictors of long-term mortality after catheter ablation of ventricular tachycardia in a contemporary cohort of patients with structural heart disease
Key result
VT ablation in structural heart disease carries ~31% mortality, linked to higher LVEDV, COPD, and AF.
- n=309
Why the study?
Although catheter ablation for VT in structural heart disease is effective and safe, long-term prognosis and outcomes remain poor.
What are the independent predictors of long-term mortality in patients with structural heart disease undergoing catheter ablation for ventricular tachycardia?
Population
309 ICM and NICM patients after ≥1 VT ablations
Comparison
ICM vs NICM patients
Design
Cohort study
Follow-up
Mean 34 ± 28 months
Authors
Discussion
Loading...
Member takes
Implication
May inform post-ablation risk stratification in structural heart disease; hypothesis-generating pending prospective validation.
Study Design
Type
Cohort (n=309)
Structured PICO
What are the independent predictors of long-term mortality in patients with structural heart disease undergoing catheter ablation for ventricular tachycardia?
P
Population
309 patients with ischaemic cardiomyopathy (ICM) and non-ischaemic cardiomyopathy (NICM) (186 ICM, 123 NICM; 271 males; mean age 64.1 ± 12 years; ejection fraction 34 ± 13%) after ≥1 VT ablations
I
Intervention
Catheter ablation of ventricular tachycardia
O
Outcome
All-cause mortalityhard clinical
In patients with structural heart disease undergoing VT ablation, higher LVEDV, male gender, COPD, AF, polymorphic VTs, antiarrhythmic use, and periprocedural complications independently predict long-term mortality.
Cite This Study
Darma et al. (2020) conducted a cohort in Ventricular tachycardia in structural heart disease (n=309). Catheter ablation was evaluated on All-cause mortality. Catheter ablation of ventricular tachycardia in structural heart disease had a 31% mortality rate over 34 months, with higher LVEDV, male gender, COPD, and AF as independent predictors.